Beta-lapachone clinical trials
Also written ARQ 501 and MB12066.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How each study uses beta-lapachone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (7) · Yungjin Pharm. Co., Ltd. (4)
Studies
Open first, then newest update. How each study uses beta-lapachone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT01285388Written as MB12066
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT02338856Written as MB12066 200mg
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy VolunteersCompletedPhase 1Yungjin Pharm. Co., Ltd.NCT01444677Written as MB12066
- Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except CirrhosisTerminatedPhase 2Yungjin Pharm. Co., Ltd.NCT02029586Written as MB12066 200mg
- An Extension Study for Patients Previously Treated With ARQ 501CompletedPhase 1/2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00622063Written as ARQ 501
- An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid TumorsCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00524524Written as ARQ 501
- Safety and Efficacy Study of ARQ 501 in Adult Patients With LeiomyosarcomaCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00310518Written as ARQ 501
- ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic CancerCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00102700Written as ARQ 501 in combination with gemcitabine
- A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00358930Written as ARQ 501
- ARQ 501 in Combination With Docetaxel in Patients With CancerCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00099190Written as ARQ 501
- ARQ 501 in Subjects With CancerCompletedPhase 1ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)NCT00075933Written as ARQ 501
Codes
What other systems call beta-lapachone · ClinicalTrials.gg INT002606
- MeSH (NLM) C014638beta-lapachoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 6N4FA2QQ6ALAPACHONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27089386lapachoneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28694LapachoneOne source FDA
- DrugBank DB11948One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C014638 | beta-lapachone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 6N4FA2QQ6A | LAPACHONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089386 | lapachone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28694 | Lapachone | One source FDA |
| DrugBank | DB11948 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.